Alpha cognition announces the commercial launch of zunveyl (benzgalantamine) for the treatment of mild to moderate alzheimer's disease

Vancouver, british columbia & dallas--(business wire)--alpha cognition inc. (nasdaq: acog), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced the official commercial launch of zunveyl, a new treatment for mild to moderate alzheimer's disease. this milestone marks a major step forward in the company's mission to provide innovative and accessible solutions for patients and caregivers — and to deliver new hope to the millions impacted by.
ACOG Ratings Summary
ACOG Quant Ranking